 |
|
Yale procedure cuts recurrence of aggressive uterine cancer
September 22, 2005A state-of-the-art treatment program developed at Yale School of Medicine increases survival from the aggressive uterine papillary serous carcinoma (UPSC) and spares some patients the need for additional therapy.
The results are presented in the lead article of September's Gynecologic Oncology. The research team, led by senior author Peter E. Schwartz, M.D., The John Slade Ely Professor of Obstetrics and Gynecology and Vice Chair and Director, determined that a combination of platinum-based chemotherapy and vaginal radiation was the most effective treatment for the disease.
"Our study defines a standard of care for this aggressive and growing form of uterine cancer," said Schwartz. The procedure more accurately determines the complete stage and appropriate treatment and reduces the recurrence of the cancer.
The incidence of UPSC has increased since it was first identified in 1981. Researchers initially thought the disease was easy to treat, but since 1990, the number of UPSC deaths has almost doubled. About 160 to 170 new cases per year are seen at Yale. UPSC is found in higher rates in African American women than in white women. The disease looks like ovarian cancer and spreads just as rapidly, therefore chemotherapy alone was traditionally used as treatment.
"Until now, there has been no consistent management of the disease," said first author Michael G. Kelly, M.D., fellow and instructor in the Department of Obstetrics, Gynecology & Reproductive Sciences at Yale. "With this method, we've been able to see who needs additional treatment after surgery and who does not. By reducing recurrence, we are helping to increase the survival rates of women with this form of uterine cancer. Once the disease recurs, virtually no one is cured."
The team reviewed 74 stage 1 patients with UPSC who underwent complete surgical staging, or hysterectomy with removal of lymph nodes and fat pads, at Yale between 1987 and 2004. Cancer recurred in 43 percent of early stage patients who did not receive chemotherapy, while in the 20 percent of patients who received platinum-based chemotherapy there were no recurrences. About 14 patients were spared additional radiation treatment.
Other authors included David M. O'Malley, Pei Hui, Jessica McAlpine, M.D., Herbert Yu, M.D., Thomas J. Rutherford, M.D., and Masoud Azodi, M.D.
Yale University
The incidence of UPSC has increased since it was first identified in 1981. Researchers initially thought the disease was easy to treat, but since 1990, the number of UPSC deaths has almost doubled. About 160 to 170 new cases per year are seen at Yale. UPSC is found in higher rates in African American women than in white women. The disease looks like ovarian cancer and spreads just as rapidly, therefore chemotherapy alone was traditionally used as treatment.
"Until now, there has been no consistent management of the disease," said first author Michael G. Kelly, M.D., fellow and instructor in the Department of Obstetrics, Gynecology & Reproductive Sciences at Yale. "With this method, we've been able to see who needs additional treatment after surgery and who does not. By reducing recurrence, we are helping to increase the survival rates of women with this form of uterine cancer. Once the disease recurs, virtually no one is cured."
The team reviewed 74 stage 1 patients with UPSC who underwent complete surgical staging, or hysterectomy with removal of lymph nodes and fat pads, at Yale between 1987 and 2004. Cancer recurred in 43 percent of early stage patients who did not receive chemotherapy, while in the 20 percent of patients who received platinum-based chemotherapy there were no recurrences. About 14 patients were spared additional radiation treatment.
Other authors included David M. O'Malley, Pei Hui, Jessica McAlpine, M.D., Herbert Yu, M.D., Thomas J. Rutherford, M.D., and Masoud Azodi, M.D.
Yale University
Uterine Cancer Current Events and Uterine Cancer News RSSHormone mix could cut breast cancer risk and treat symptoms of menopause
The right combination of estrogen and a selective estrogen receptor modulator (SERM), which blocks the effects of estrogen in breast tissue, could relieve menopause symptoms and cut breast cancer risk.
New drug aims to 'seek and destroy' many types of cancer
A new drug designed to "seek and destroy" common cancers such as breast, prostate, endometrial, pancreatic, ovarian, skin and testicular cancers is being tested at TGen Clinical Research Services (TCRS) at Scottsdale Healthcare.
Study identifies how tamoxifen stimulates uterine cell growth and cancer
UCSF researchers have identified a new "feed-forward" pathway linking estrogen receptors in the membrane of the uterus to a process that increases local estrogen levels and promotes cell growth.
Black women with uterine cancers more likely to die than white patients
Black women with cancers of the uterus are less likely to survive the disease than white women, and relatively little progress has been made over the past two decades to narrow this racial difference. That is the conclusion of a new study published in the March 15, 2009 issue of CANCER, a peer-reviewed journal of the American Cancer Society.
New research findings may enable earlier diagnosis of uterine cancer
Cancer is a genetic disease. It occurs when changes take place in the genes that regulate cell division, cell growth, cell death, cell signalling and blood vessel formation - either due to mutations caused by external factors such as smoking or radiation - or due to inherited changes.
2 new compounds show promise for eliminating breast cancer tumors
Two new compounds created by a University of Central Florida professor show early promise for destroying breast cancer tumors.
Hormone drug type makes survival difference in advanced breast cancer
Aromatase inhibitors, a type of hormone therapy used to treat advanced breast cancer in postmenopausal women, result in a small but significant increase in overall survival when compared to other hormone treatments, according to a new systematic review of studies.
Two new studies reveal benefits of laparoscopic surgery for uterine cancer
In a pair of studies presented today at the Society of Gynecologic Oncologists 37th Annual Meeting on Women's Cancer, researchers have found in a large randomized trial of laparoscopy versus laparotomy for surgical treatment of uterine (endometrial) cancer that laparoscopy is safe, and when successfully completed reduces hospital stay by 50 percent, and contributes to a better quality of life from the patient's perspective.
Studies find no evidence that estrogens in soy increase uterine cancer risk
Studies in monkeys and women suggest that unlike traditional estrogen therapy, a diet high in the natural plant estrogens found in soy does not increase the risk of uterine cancer in postmenopausal women.
Detection of glycoprotein could identify ovarian and uterine cancers with poor prognosis (p 865)
Issue 13 September 2003 Embargoed 0001 h (London time) 12 September 2003. The detection of a specific protein molecule could help oncologists identify uterine and ovarian cancers with poor prognosis and thereby enable better disease management of women with aggressive uterine or ovarian cancer, suggest authors of a study in this week's issue of THE LANCET. Ovarian and uterine cancer is the most common cause of death from cancer-related deaths for women with gynaecological malignant disease. The prognosis for women with uterine cancer is usually better than for women with ovarian cancer; however some women will develop aggressive tumours in either disease which increases the risk of death.
More Uterine Cancer Current Events and Uterine Cancer News Articles
 |
Johns Hopkins Patients' Guide to Uterine Cancer (John Hopkins Medicine) by Teresa P. Diaz-Montes (Author) The Johns Hopkins Patients Guide to Uterine Cancer is a concise, easy-to-follow how to guide that puts you on a path to wellness by explaining uterine cancer treatments from start to finish. It guides you through the overwhelming maze of treatment decisions, simplifies the complicated schedule that lies ahead, and provides valuable tools to help you to put together your plan of care. Empower yourself with accurate, understandable information that will give you the ability to confidently participate in the decision making about your care and treatment. |
 |
Permanent Healing: Surviving Stage III Uterine Cancer Seven Years after Chemotherapy by Dale Louise Evje (Author) People didn't notice I was struggling. Also I couldn't find the words to speak that I was in distress. I went down once, tried to swim, saw the two turtles swimming below, and was completely awed and excited. But then I started, accidentally swallowing water. I surfaced, and sputtered, and spit, trying to catch my breath. The turtles told me to get out of the water and go to shore. Telepathically, they sent me this very clear, concise silent message, "Now, Dale, there is something wrong with you. Save yourself! Don't come down here, don't go any further. Go back to shore." Dale Evje's approach to wellness affirms that healing is a holistic process, and that includes a consciousness that seeks inner peace, acknowledges grace with gratitude, and practices compassion for oneself and... |
 |
100 Pack Teal Blue Ribbon Temporary Tattoos for Ovarian Cervical Uterine Cancer Awareness by Palmetto Fundraising Show your courage and support! These teal ribbon tattoos are perfect for your next awareness event. These tattoos make great inspirational giveaways. 100 tattoos per package. Teal ribbon design with clear sides. Approximately 1.5" x 2". These cancer awareness favors are perfect for your awareness fundraisers or event. |
 |
Beating Uterine Cancer Together T-shirt Large White by Shop Zeus |
 |
Beating Uterine Cancer Together Mug by Design a Product LLC Text on mug: Beating Uterine Cancer Together * Custom coffee mugs are dishwasher-safe and microwave-safe. Colors are permanently baked into the mug''s surface. * If you have new ideas or need help selecting text for your custom coffee mugs please contact us. * Size: 11 oz. capacity ceramic coffee mug. |
 |
Uterine Cancer by David M. Luesley (Editor), Frank Lawton (Editor), Andrew Berchuck (Editor) This authoritative reference compiles the latest studies on the epidemiology, diagnosis, and treatment of uterine cancer and offers an extensive review of the molecular pathogenesis of endometrial and uterine disorders-analyzing patterns of disease presentation as population demographics change and considering the challenges this will place on future healthcare procedures. |
|
Uterine Cancer Awareness Ribbon Mouse Pad by MyHeritageWear.com The Uterine Cancer Ribbon proudly displayed on a mouse pad. There is no better way to achieve awareness for the meaning of the Uterine Cancer Ribbon than to display it on your mouse pad for everyone to see. The mouse pad measures at 9.25 x 7.75, it is machine washable, and the colors will not fade or run. Start gaining awareness today by presenting your Uterine Cancer Ribbon mouse pad at work or at home. It is certain to keep your mouse rolling in style all while gaining support and awareness! | |
 |
Cancer Schmancer by Fran Drescher (Author) From Fran Drescher, here's the funny and empowering New York Times bestseller about taking charge of health problems and finding humor in the face of adversity. Part inspirational cancer-survival story, part memoir-as-a-laugh-riot, CANCER SCHMANCER picks up where Fran's last book, Enter Whining, left off. After the publication of that book, Fran's life launched into a downward spiral. She separated from a long and complicated relationship, her TV series started to slip in the ratings, and the health of her beloved dog Chester was failing fast. Then came the mysterious symptoms no doctor could explain. With her trademark sense of humor, Fran tells of her long search for answers and the cancer diagnosis that she ultimately beat. But not before a gold mine of insights were revealed to her... |
 |
Beating Uterine Cancer Together Long Sleeve T-shirt Large White by Shop Zeus |
 |
Uterine Cancer: Screening, Diagnosis, and Treatment (Current Clinical Oncology) by Franco Muggia (Editor), Esther Oliva (Editor) There are an estimated 41,000 new cases of Uterine and Endometrial Cancer each year in the United States alone, resulting in roughly 7300 deaths. In Uterine Cancer: Screening, Diagnosis and Treatment, Franco Muggia, Esther Oliva and a panel of prominent medical and gynecologic oncologists survey all aspects of Uterine and Endometrial Cancer, including current screening methods, staging and prognostic factors, and available treatment options. The discussion includes the role of imaging in the diagnosis and treatment of endometrial cancer, the molecular pathology and genetics of uterine cancer and the essential epidemiology of cancer of the endometrium. Authoritative and highly practical, Uterine Cancer: Screening, Diagnosis and Treatment is the definitive text on the most common cancer... |
| © 2009 BrightSurf.com |